RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
about
ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPKLocalization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cellsProbing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells.PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1)Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.Urokinase and its receptors in chronic kidney disease.Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasionCrosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis(±)Equol inhibits invasion in prostate cancer DU145 cells possibly via down-regulation of matrix metalloproteinase-9, matrix metalloproteinase-2 and urokinase-type plasminogen activator by antioxidant activity.uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.A Long-Gap Peripheral Nerve Injury Therapy Using Human Skeletal Muscle-Derived Stem Cells (Sk-SCs): An Achievement of Significant Morphological, Numerical and Functional RecoveryDesign, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor.Simultaneous knockdown of uPA and MMP9 can reduce breast cancer progression by increasing cell-cell adhesion and modulating EMT genes.Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myelomaRNAi-mediated downregulation of radiation-induced MMP-9 leads to apoptosis via activation of ERK and Akt in IOMM-Lee cells.Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis.Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cellsReactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy.Concepts in in vivo siRNA delivery for cancer therapy.Human adipose-derived stem cell adipogenesis induces paracrine regulation of the invasive ability of MCF-7 human breast cancer cells in vitro.Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases.Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.Urokinase plasminogen activator system as a potential target for cancer therapy.Potential clinical applications of siRNA technique: benefits and limitations.Leveraging therapeutic potential of multi-targeted siRNA inhibitors.A novel peptide blocking cancer cell invasion by structure-based drug design.uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell lineAdditive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop in medulloblastoma cells.Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma.Breast cancer characteristics are modified by first trimester human placenta: in vitro co-culture study.RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells.Inhibition of laryngeal cancer cell invasion and growth with lentiviral-vector delivered short hairpin RNA targeting human MMP-9 gene.The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins.Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells.Effect of dietary β carotene on cerebral aneurysm and subarachnoid haemorrhage in the brain apo E-/- mice.Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma.
P2860
Q24296295-2F48D34A-4AF1-4555-8B22-0E395FB32988Q33755491-CF83AE88-2DE5-4E3B-9A98-2097AE85AAE1Q33758094-F590B335-848D-4220-9C8C-7DD4C4F1B4FBQ34057949-8EC1DB1E-D2F1-4D90-AD6E-D326CC2CAD7AQ34191636-6C3AB14B-4AFA-4696-BD5F-27E28D37E0E7Q34490917-CD73DEF9-987D-42EC-A328-25527D76927CQ34587758-93AB2D66-8047-4BD0-A553-0F2E89649549Q35124141-27226889-F526-4AAD-9C6D-C2F5BF5A8ED0Q35563311-A217C3DE-77CA-43A3-8C65-834554687B80Q35840236-25F199A0-1DB2-4FA7-8951-144111EB09D5Q36082397-1BDC3A64-F396-434E-A428-5BA8125434BAQ36097941-DD07B3E7-4514-4435-8D10-2A0AD287B94CQ36193040-7D1AA8AF-D5B4-4858-A67E-B9389EF89518Q36221040-878C78E7-A47B-48C9-8788-38D434AB7632Q36610815-6C4B99BF-3C93-48A4-83F6-DC1F0C7ECDCBQ36973696-A629FD9A-B48C-4AA0-B093-9176E220DDCFQ37020853-E1077B34-23D0-4CA5-A7CA-A62C86D48452Q37087120-6E41A127-DB74-4D1A-9845-9EC273198E00Q37132905-0743AC79-525A-44F5-AEF6-70D81B50C9B3Q37135987-6B200E5D-1374-4028-BABD-06141722F0FEQ37217876-0F4BE072-9F86-456A-BE56-5D2C587FC6B0Q37231266-409F6022-29A2-46F3-B714-49C9AF0EBD89Q37419308-C8E7EC95-3470-4F53-A3B8-AD4F4041D62BQ37536780-C56DAE82-DFB1-4C57-A4F2-91FE92001DF1Q37630593-721CFF3D-5171-4E2D-9373-0F295809362CQ37801965-5BF9F585-FB9C-48CA-8504-46555FD1A311Q37855818-D87A564F-E9F5-491F-AA88-8FADDFCF2280Q38694644-C4D9B633-C2C0-463F-8213-EE664E887599Q38817198-6C3CA4C7-B648-4197-B7FF-58B39C57C07FQ38954660-17EE42F7-739B-4E37-A2B9-1BD8F0C61FD0Q39144769-B2967DCE-656E-434D-A05B-7A862B987FDDQ39589853-43A22BC9-01BF-4BC0-BC9C-B1B2DADAB9CBQ39666041-3F4065D0-D3A7-4E5E-AA62-29F43CC59138Q39753797-20B0CC72-7C4C-4159-B1D3-16FC1D2C8D86Q39903884-11919110-95EE-4527-8D7C-5294CD850F40Q41874995-7984F67E-A537-489F-AB1E-8EAFEB6CD83FQ46483152-F4C54BE9-6CA2-427F-83D7-53B04E8452D9Q49016420-C444293D-0ECC-45D5-AF60-21A9B1A96C63Q52956238-05DA5D91-446B-47C4-8EC7-633255EAA5FCQ53285654-F43958D3-CB5F-43DB-860B-8917C524526E
P2860
RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
RNAi-mediated downregulation o ...... sion, angiogenesis and growth.
@ast
RNAi-mediated downregulation o ...... sion, angiogenesis and growth.
@en
type
label
RNAi-mediated downregulation o ...... sion, angiogenesis and growth.
@ast
RNAi-mediated downregulation o ...... sion, angiogenesis and growth.
@en
prefLabel
RNAi-mediated downregulation o ...... sion, angiogenesis and growth.
@ast
RNAi-mediated downregulation o ...... sion, angiogenesis and growth.
@en
P2093
P2860
P356
P1476
RNAi-mediated downregulation o ...... asion, angiogenesis and growth
@en
P2093
Jasti S Rao
Norman Estes
Sajani S Lakka
Sateesh Kunigal
P2860
P304
P356
10.1002/IJC.22962
P577
2007-11-01T00:00:00Z